Lombard Odier Asset Management (USA)’s Trillium Therapeutics Inc. TRIL Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-50,000	Closed	-$878K	–	490
2021 Q3	$878K	Buy	+50,000	New	+$584K	0.04%	226

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s TRIL Position: Q4 2021 in Review

Lombard Odier Asset Management (USA) sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 50,000 shares — an estimated $878K sold.

Lombard Odier Asset Management (USA) first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $878K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Lombard Odier Asset Management (USA) reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Lombard Odier Asset Management (USA) sold 50,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $878K.
Lombard Odier Asset Management (USA) first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Lombard Odier Asset Management (USA)'s Trillium Therapeutics Inc. position peaked at $878K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q4 2021, filed 14 Feb 2022.